Literature DB >> 28403048

Prevalence of Mycoplasma pneumoniae Infection in Malagasy Children.

Lova Ravelomanana1, Naim Bouazza, Mbola Rakotomahefa, André Zo Andrianirina, Annick Lalaina Robinson, Honoré Raobidjaona, Rabezanahary Andriamihaja, Nadjet Benhaddou, Fréderique Randrianirina, Elisoa Ratsima, Patrick Imbert, Josette Raymond.   

Abstract

BACKGROUND: Childhood community-acquired pneumonia is a leading cause of childhood morbidity in low-income countries. The etiologic agents are usually Staphylococcus aureus, Streptococcus pneumoniae and Mycoplasma pneumoniae. M. pneumoniae was recognized as a cofactor in asthmatic disease. High asthma prevalence was reported in Madagascar. Our aim was to clarify the prevalence of M. pneumoniae infection in this country and its relationship with asthma.
METHODS: A prospective study was conducted in 351 children (from 2 to 16 years of age) from January 2012 to December 2014. According to the clinical symptoms, children were enrolled in 3 groups: "control group" (CG, n = 106), "asthma group" (n = 129) and "pneumonia group" (n = 116). The IgG and IgM M. pneumoniae status was evaluated by an enzyme-linked immunosorbent assay. Clinical signs of infection, socioeconomic data and antimicrobial treatment were recorded.
RESULTS: The overall prevalence of M. pneumoniae infection was 18.2%. The multivariate analysis demonstrated that M. pneumoniae infection was significantly more frequent in the CG [pneumonia group vs. CG: odds ratio = 0.45 (0.21-0.91), P = 0.037 and asthma group vs. CG: odds ratio = 0.39 (0.18-0.87), P = 0.021]. The C-reactive protein value was significantly higher in children with M. pneumonia-positive serology (85 vs. 61 mg/L, P = 0.03). Of note, 99 (41%) children received antibiotics before attending.
CONCLUSIONS: We report a prevalence of 18.2% for M. pneumoniae infection in children in Madagascar. The prevalence of M. pneumoniae infection was higher in the control patients than in asthmatic ones.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28403048     DOI: 10.1097/INF.0000000000001471

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  5 in total

1.  Evaluation of variation in coagulation among children with Mycoplasma pneumoniae pneumonia: a case-control study.

Authors:  Tianhua Li; Haiying Yu; Weina Hou; Zhiyong Li; Chunfang Han; Lihong Wang
Journal:  J Int Med Res       Date:  2017-06-23       Impact factor: 1.671

Review 2.  Comparative efficacy of Chinese herbal injections combined with azithromycin for mycoplasma pneumonia in children: A Bayesian network meta-analysis of randomized controlled trials.

Authors:  Xiaojiao Duan; Kaihuan Wang; Jiarui Wu; Dan Zhang; Xinkui Liu; Mengwei Ni; Shuyu Liu; Ziqi Meng
Journal:  J Clin Pharm Ther       Date:  2019-05-22       Impact factor: 2.512

3.  Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia.

Authors:  Xia Huang; Dan Li; Feng Liu; Deyu Zhao; Yifan Zhu; Heng Tang
Journal:  BMC Infect Dis       Date:  2021-01-06       Impact factor: 3.090

4.  Evaluation on blood coagulation and C-reactive protein level among children with mycoplasma pneumoniae pneumonia by different chest imaging findings.

Authors:  Juan Wang; Jianping Mao; Gang Chen; Yuanmei Huang; Jinjin Zhou; Changlong Gao; Danting Jin; Chenying Zhang; Juan Wen; Jun Sun
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 5.  Differential Markers of Bacterial and Viral Infections in Children for Point-of-Care Testing.

Authors:  Yu-Ting Tsao; Yao-Hung Tsai; Wan-Ting Liao; Ching-Ju Shen; Ching-Fen Shen; Chao-Min Cheng
Journal:  Trends Mol Med       Date:  2020-09-29       Impact factor: 11.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.